IRIS
CIARDIELLO, Fortunato
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 34.641
NA - Nord America 19.477
AS - Asia 14.820
SA - Sud America 2.411
Continente sconosciuto - Info sul continente non disponibili 1.063
AF - Africa 171
OC - Oceania 32
Totale 72.615
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 22.162
US - Stati Uniti d'America 19.121
SG - Singapore 5.295
IE - Irlanda 3.520
CN - Cina 3.083
HK - Hong Kong 2.511
BR - Brasile 2.038
IT - Italia 1.807
UA - Ucraina 1.726
VN - Vietnam 1.627
GB - Regno Unito 1.616
DE - Germania 1.295
FR - Francia 640
KR - Corea 614
FI - Finlandia 538
SE - Svezia 470
IN - India 430
GR - Grecia 352
TR - Turchia 346
JP - Giappone 257
CA - Canada 196
BD - Bangladesh 167
AR - Argentina 134
NL - Olanda 113
AT - Austria 92
ID - Indonesia 88
MX - Messico 83
PK - Pakistan 80
IQ - Iraq 71
PL - Polonia 70
EC - Ecuador 69
ES - Italia 51
CO - Colombia 49
BE - Belgio 47
ZA - Sudafrica 38
VE - Venezuela 37
MA - Marocco 33
CZ - Repubblica Ceca 30
SA - Arabia Saudita 29
PY - Paraguay 28
CH - Svizzera 26
CL - Cile 26
AU - Australia 23
JO - Giordania 19
EG - Egitto 17
IL - Israele 17
TH - Thailandia 17
AE - Emirati Arabi Uniti 16
AZ - Azerbaigian 16
IR - Iran 16
KE - Kenya 16
TN - Tunisia 16
UZ - Uzbekistan 16
EU - Europa 15
JM - Giamaica 15
PH - Filippine 15
DZ - Algeria 14
AL - Albania 13
NP - Nepal 13
CR - Costa Rica 12
DO - Repubblica Dominicana 12
LT - Lituania 12
MY - Malesia 12
PE - Perù 11
BO - Bolivia 10
HN - Honduras 10
HU - Ungheria 9
TW - Taiwan 9
KG - Kirghizistan 8
NZ - Nuova Zelanda 8
SN - Senegal 8
LB - Libano 7
TT - Trinidad e Tobago 7
HR - Croazia 6
KZ - Kazakistan 6
PT - Portogallo 6
UY - Uruguay 6
AO - Angola 5
BH - Bahrain 5
BY - Bielorussia 5
CG - Congo 5
GT - Guatemala 5
RO - Romania 5
RS - Serbia 5
ET - Etiopia 4
LV - Lettonia 4
MK - Macedonia 4
NI - Nicaragua 4
OM - Oman 4
BB - Barbados 3
BG - Bulgaria 3
GY - Guiana 3
KW - Kuwait 3
MM - Myanmar 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
CI - Costa d'Avorio 2
EE - Estonia 2
GA - Gabon 2
GI - Gibilterra 2
Totale 71.521
Salva come PNG Salva come JPEG
Città #
Moscow 7.948
Dublin 3.502
Jacksonville 2.644
Hong Kong 2.472
San Jose 2.233
Singapore 2.034
Santa Clara 1.985
Chandler 1.692
Ashburn 975
Wilmington 695
Chicago 626
Seoul 584
Princeton 558
Ho Chi Minh City 547
Medford 493
Hefei 452
New York 400
Hanoi 374
Beijing 355
Falls Church 334
Boardman 311
Naples 297
Dallas 294
San Mateo 292
Bengaluru 289
Council Bluffs 287
Roxbury 257
Ann Arbor 250
Bremen 231
Los Angeles 221
Munich 211
The Dalles 210
Caserta 184
São Paulo 174
Woodbridge 161
Cambridge 124
Des Moines 120
Nanjing 97
Da Nang 92
Nuremberg 85
Houston 77
Haiphong 71
Rio de Janeiro 65
Jinan 64
Milan 62
Elora 59
Orem 58
Shanghai 58
Turku 57
Amsterdam 54
Mountain View 53
Atlanta 51
Belo Horizonte 51
Napoli 50
Tokyo 50
Vienna 50
Rome 44
Frankfurt am Main 43
Aversa 42
Dong Ket 42
Helsinki 42
Norwalk 42
Düsseldorf 41
Brussels 40
Brooklyn 39
Tianjin 39
Guangzhou 36
Nanchang 36
Warsaw 36
Curitiba 35
Brasília 34
Lappeenranta 34
Montreal 34
Hải Dương 33
London 32
Phoenix 32
Chennai 31
Falkenstein 31
San Francisco 30
Quito 28
Campinas 27
Changsha 27
Memphis 27
Shenyang 27
Columbus 26
Kraków 26
Manchester 26
Jakarta 25
Ninh Bình 25
Biên Hòa 24
Guarulhos 24
Istanbul 24
Thái Bình 24
Brno 23
Goiânia 23
Hillsboro 23
Auburn Hills 22
Porto Alegre 22
Ribeirão Preto 22
Salvador 22
Totale 37.385
Salva come PNG Salva come JPEG
Nome #
Epigenetic mechanisms underlying prostate cancer radioresistance 1.430
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 312
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 253
Beyond N staging in colorectal cancer: Current approaches and future perspectives 226
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 211
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis 211
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. 209
ONCOLOGIA MEDICA 209
A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non-Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. 208
AXL is an oncotarget in human colorectal cancer 197
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? 196
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients 195
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials 195
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 193
Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis 189
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 189
Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma—a pilot study. Curr Oncol 21, 3, june 2014 125-133 188
A trimodality, four-step treatment including chemotherapy, pleurectomy/decortication and radiotherapy in early-stage malignant pleural mesothelioma: A single-institution retrospective case series study 188
Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review 187
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 187
A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells 186
Adjuvant chemoradiotherapy in patients with stage III-IV radically resected gastric cancer: a pilot study 186
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 185
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 184
CBX2 shapes chromatin accessibility promoting AML via p38 MAPK signaling pathway 181
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 181
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 179
A possible connective tissue primary lymphoepithelioma-like carcinoma (LELC). 179
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 178
Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: A propensity score-matched analysis 178
Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells 178
A preliminary study for quantitative assessment with HFUS (High-frequency ultrasound) of nodular skin melanoma breslow thickness in adults before surgery: Interdisciplinary team experience 177
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 176
Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study) 175
Chronic inflammation and oxidative stress in human carcinogenesis 175
Immunotherapy for head and neck cancer: Present and future 175
Cancer Treatment–Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy 173
Intraoperative ultrasound: "Alternative eye" in lymph nodal dissection in non-small cell lung cancer 172
Clinical management of advanced gastric cancer: Role of new molecular drugs. 170
Modified blade: an interventional option in rigid bronchoscopy for non-resectable benign tracheal stenosis 169
A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics 168
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 168
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 166
Intraoperative ventilatory leak: Real-time guidance for management of air leak in lung cancer patients undergoing VATS lobectomy 165
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 164
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 164
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 164
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 164
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 164
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 163
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 163
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 162
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 162
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 162
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 161
CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial 161
Prediction of preoperative intrathoracic adhesions for ipsilateral reoperations: sliding lung sign 161
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 160
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 160
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 160
Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics 159
Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials 158
Treatment of gastric cancer. 157
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer 155
Conversion chemotherapy followed by epatic resection in colorectal cancer with initially unresectable liver-limited metastases 155
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 155
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 154
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 154
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations 153
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 153
Clinical activity of regorafenib in elderly patients with recurrent glioblastoma 152
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 152
AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma 152
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. 152
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer 152
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 152
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 151
1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. 150
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 150
Clinical management of metastatic colorectal cancer in the era of precision medicine 150
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 149
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial 149
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy 149
Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota 149
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 148
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 148
Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer 148
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 148
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 147
Intraoperative lung ultrasound improves subcentimetric pulmonary nodule localization during VATS: Results of a retrospective analysis 147
8-chloro-cAMP enhances the growth inhibitory effect of cytotoxic drugs in humancolon cancer cells 147
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 147
Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis 146
Pimasertib hydrochloride 146
Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers 146
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 145
TGF-β Modulated Pathways in Colorectal Cancer: New Potential Therapeutic Opportunities 144
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors 144
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 143
Addition of metformin to anti-PD-1/PD-L1 drugs activates anti- tumor immune response in peripheral immune cells of NSCLC patients 143
Totale 18.191
Salva come PNG Salva come JPEG
Categoria #
all - tutte 260.424
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 260.424
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.783 0 171 288 158 1.304 73 83 114 159 165 300 968
2022/20237.055 796 176 392 603 674 567 31 366 3.135 44 136 135
2023/20242.895 245 89 130 249 998 337 61 61 48 27 199 451
2024/20258.974 97 169 120 305 1.245 1.098 894 846 1.204 1.773 650 573
2025/202638.004 1.423 1.752 2.045 1.998 2.916 20.660 2.002 1.721 1.460 1.040 600 387
2026/20271.472 496 976 0 0 0 0 0 0 0 0 0 0
Totale 72.615